{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:45:09Z","timestamp":1790210709737,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-71040-8","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:03:36Z","timestamp":1775725416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fc-free single-chain antibody mRNA therapy for airway infection of multidrug-resistant Pseudomonas aeruginosa"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-8764","authenticated-orcid":false,"given":"Mao","family":"Kinoshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7546-3088","authenticated-orcid":false,"given":"Ken","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5559-8519","authenticated-orcid":false,"given":"Yuki","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen B. T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0986-3446","authenticated-orcid":false,"given":"Atsushi","family":"Kainuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7238-3352","authenticated-orcid":false,"given":"Naoko","family":"Takeda-Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9558-9011","authenticated-orcid":false,"given":"Teiji","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8726-0478","authenticated-orcid":false,"given":"Satoshi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"71040_CR1","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","volume":"25","author":"H Sati","year":"2025","unstructured":"Sati, H. et al. The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. Lancet Infect. Dis. 25, 1033\u20131043 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"71040_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray, C. J. L. & GBD 2021 Antimicrobial Resistance Collaborators Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629\u2013655 (2022).","journal-title":"Lancet"},{"key":"71040_CR3","unstructured":"O\u2019Neill, J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on Antimicrobial Resistance, https:\/\/wellcomecollection.org\/works\/rdpck35v (2014)."},{"key":"71040_CR4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"M Naghavi","year":"2024","unstructured":"Naghavi, M. & GBD 2021 Antimicrobial Resistance Collaborators Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. Lancet 404, 1199\u20131226 (2024).","journal-title":"Lancet"},{"key":"71040_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41579-023-00993-0","volume":"22","author":"CR MacNair","year":"2024","unstructured":"MacNair, C. R., Rutherford, S. T. & Tan, M. W. Alternative therapeutic strategies to treat antibiotic-resistant pathogens. Nat. Rev. Microbiol. 22, 262\u2013275 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"71040_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2165\/00003495-200767030-00003","volume":"67","author":"JA Driscoll","year":"2007","unstructured":"Driscoll, J. A., Brody, S. L. & Kollef, M. H. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 67, 351\u2013368 (2007).","journal-title":"Drugs"},{"key":"71040_CR7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","volume":"81","author":"D Reynolds","year":"2021","unstructured":"Reynolds, D. & Kollef, M. The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update. Drugs 81, 2117\u20132131 (2021).","journal-title":"Drugs"},{"key":"71040_CR8","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1128\/IAI.66.7.3242-3249.1998","volume":"66","author":"T Sawa","year":"1998","unstructured":"Sawa, T. et al. In vitro cellular toxicity predicts Pseudomonas aeruginosa virulence in lung infections. Infect. Immun. 66, 3242\u20133249 (1998).","journal-title":"Infect. Immun."},{"key":"71040_CR9","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1128\/IAI.00815-08","volume":"77","author":"M Baer","year":"2009","unstructured":"Baer, M. et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect. Immun. 77, 1083\u20131090 (2009).","journal-title":"Infect. Immun."},{"key":"71040_CR10","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.4161\/21645515.2014.971641","volume":"10","author":"T Sawa","year":"2014","unstructured":"Sawa, T., Ito, E., Nguyen, V. H. & Haight, M. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa. Hum. Vaccin Immunother. 10, 2843\u20132852 (2014).","journal-title":"Hum. Vaccin Immunother."},{"key":"71040_CR11","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1097\/CCM.0b013e31825334f6","volume":"40","author":"B Francois","year":"2012","unstructured":"Francois, B. et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial. Crit. Care Med. 40, 2320\u20132326 (2012).","journal-title":"Crit. Care Med."},{"key":"71040_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ppul.22890","volume":"49","author":"CE Milla","year":"2014","unstructured":"Milla, C. E. et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr. Pulmonol. 49, 650\u2013658 (2014).","journal-title":"Pediatr. Pulmonol."},{"key":"71040_CR13","doi-asserted-by":"publisher","first-page":"629 e621","DOI":"10.1016\/j.cmi.2018.08.004","volume":"25","author":"SO Ali","year":"2019","unstructured":"Ali, S. O. et al. Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clin. Microbiol. Infect. 25, 629 e621\u2013629 e626 (2019).","journal-title":"Clin. Microbiol. Infect."},{"key":"71040_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04204-9","volume":"26","author":"J Chastre","year":"2022","unstructured":"Chastre, J. et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit. Care 26, 355 (2022).","journal-title":"Crit. Care"},{"key":"71040_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1586\/14760584.2014.890053","volume":"13","author":"GP Priebe","year":"2014","unstructured":"Priebe, G. P. & Goldberg, J. B. Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev. Vaccines 13, 507\u2013519 (2014).","journal-title":"Expert Rev. Vaccines"},{"key":"71040_CR16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/7391","volume":"5","author":"T Sawa","year":"1999","unstructured":"Sawa, T. et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat. Med. 5, 392\u2013398 (1999).","journal-title":"Nat. Med."},{"key":"71040_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/amp2.10060","volume":"2","author":"Z Kis","year":"2020","unstructured":"Kis, Z., Kontoravdi, C., Dey, A. K., Shattock, R. & Shah, N. Rapid development and deployment of high-volume vaccines for pandemic response. J. Adv. Manuf. Process 2, e10060 (2020).","journal-title":"J. Adv. Manuf. Process"},{"key":"71040_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.ymthe.2019.03.002","volume":"27","author":"T Schlake","year":"2019","unstructured":"Schlake, T. et al. mRNA: a novel avenue to antibody therapy? Mol. Ther. 27, 773\u2013784 (2019).","journal-title":"Mol. Ther."},{"key":"71040_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"71040_CR20","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s41586-024-07266-7","volume":"628","author":"D Koeberl","year":"2024","unstructured":"Koeberl, D. et al. Interim analyses of a first-in-human phase 1\/2 mRNA trial for propionic acidaemia. Nature 628, 872\u2013877 (2024).","journal-title":"Nature"},{"key":"71040_CR21","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1016\/j.ymthe.2025.03.034","volume":"33","author":"MM Zak","year":"2025","unstructured":"Zak, M. M. & Zangi, L. Clinical development of therapeutic mRNA applications. Mol. Ther. 33, 2583\u20132609 (2025).","journal-title":"Mol. Ther."},{"key":"71040_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14630","volume":"8","author":"N Pardi","year":"2017","unstructured":"Pardi, N. et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun. 8, 14630 (2017).","journal-title":"Nat. Commun."},{"key":"71040_CR23","doi-asserted-by":"publisher","first-page":"eaaw6647","DOI":"10.1126\/sciimmunol.aaw6647","volume":"4","author":"N Kose","year":"2019","unstructured":"Kose, N. et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci. Immunol. 4, eaaw6647 (2019).","journal-title":"Sci. Immunol."},{"key":"71040_CR24","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.ymthe.2019.05.012","volume":"27","author":"Y Rybakova","year":"2019","unstructured":"Rybakova, Y. et al. mRNA delivery for therapeutic anti-HER2 antibody expression in vivo. Mol. Ther. 27, 1415\u20131423 (2019).","journal-title":"Mol. Ther."},{"key":"71040_CR25","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","volume":"27","author":"A August","year":"2021","unstructured":"August, A. et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat. Med. 27, 2224\u20132233 (2021).","journal-title":"Nat. Med."},{"key":"71040_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41422-022-00630-0","volume":"32","author":"YQ Deng","year":"2022","unstructured":"Deng, Y. Q. et al. Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. Cell Res. 32, 375\u2013382 (2022).","journal-title":"Cell Res."},{"key":"71040_CR27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.7150\/jca.63991","volume":"13","author":"L Wu","year":"2022","unstructured":"Wu, L. et al. Intravenous delivery of RNA encoding anti-PD-1 human monoclonal antibody for treating intestinal cancer. J. Cancer 13, 579\u2013588 (2022).","journal-title":"J. Cancer"},{"key":"71040_CR28","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.ymthe.2024.05.036","volume":"32","author":"C Tkaczyk","year":"2024","unstructured":"Tkaczyk, C. et al. In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infection. Mol. Ther. 32, 2505\u20132518 (2024).","journal-title":"Mol. Ther."},{"key":"71040_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/19420862.2015.1113360","volume":"8","author":"F Unverdorben","year":"2016","unstructured":"Unverdorben, F. et al. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. MAbs 8, 120\u2013128 (2016).","journal-title":"MAbs"},{"key":"71040_CR30","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1126\/science.1118476","volume":"310","author":"CA Mueller","year":"2005","unstructured":"Mueller, C. A. et al. The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles. Science 310, 674\u2013676 (2005).","journal-title":"Science"},{"key":"71040_CR31","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1111\/j.1365-2958.2007.05871.x","volume":"65","author":"P Broz","year":"2007","unstructured":"Broz, P. et al. Function and molecular architecture of the Yersinia injectisome tip complex. Mol. Microbiol. 65, 1311\u20131320 (2007).","journal-title":"Mol. Microbiol."},{"key":"71040_CR32","doi-asserted-by":"publisher","first-page":"6507","DOI":"10.1073\/pnas.0708344105","volume":"105","author":"AJ Blocker","year":"2008","unstructured":"Blocker, A. J. et al. What\u2019s the point of the type III secretion system needle? Proc. Natl. Acad. Sci. USA 105, 6507\u20136513 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71040_CR33","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nm.4356","volume":"23","author":"CR Stadler","year":"2017","unstructured":"Stadler, C. R. et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat. Med. 23, 815\u2013817 (2017).","journal-title":"Nat. Med."},{"key":"71040_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1476-8518-1-2","volume":"1","author":"K Faure","year":"2003","unstructured":"Faure, K. et al. Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model. J. Immune Based Ther. Vaccines 1, 2 (2003).","journal-title":"J. Immune Based Ther. Vaccines"},{"key":"71040_CR35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1006\/bbrc.1994.1736","volume":"201","author":"K Tsumoto","year":"1994","unstructured":"Tsumoto, K. et al. Effect of the order of antibody variable regions on the expression of the single-chain HyHEL10 Fv fragment in E. coli and the thermodynamic analysis of its antigen-binding properties. Biochem. Biophys. Res Commun. 201, 546\u2013551 (1994).","journal-title":"Biochem. Biophys. Res Commun."},{"key":"71040_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1046\/j.1365-2958.1997.4891851.x","volume":"25","author":"V Finck-Barbancon","year":"1997","unstructured":"Finck-Barbancon, V. et al. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol. Microbiol. 25, 547\u2013557 (1997).","journal-title":"Mol. Microbiol."},{"key":"71040_CR37","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1165\/rcmb.2009-0210ST","volume":"44","author":"G Matute-Bello","year":"2011","unstructured":"Matute-Bello, G. et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am. J. Respir. Cell Mol. Biol. 44, 725\u2013738 (2011).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"71040_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/2052-0492-2-10","volume":"2","author":"T Sawa","year":"2014","unstructured":"Sawa, T. The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response. J. Intensive Care 2, 10 (2014).","journal-title":"J. Intensive Care"},{"key":"71040_CR39","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jiac.2018.03.008","volume":"24","author":"A Kainuma","year":"2018","unstructured":"Kainuma, A. et al. An outbreak of fluoroquinolone-resistant Pseudomonas aeruginosa ST357 harboring the exoU gene. J. Infect. Chemother. 24, 615\u2013622 (2018).","journal-title":"J. Infect. Chemother."},{"key":"71040_CR40","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrmicro2199","volume":"7","author":"AR Hauser","year":"2009","unstructured":"Hauser, A. R. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat. Rev. Microbiol 7, 654\u2013665 (2009).","journal-title":"Nat. Rev. Microbiol"},{"key":"71040_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.micpath.2010.02.008","volume":"48","author":"SV Lynch","year":"2010","unstructured":"Lynch, S. V. et al. Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - implications for anti-PcrV immunotherapy. Micro. Pathog. 48, 197\u2013204 (2010).","journal-title":"Micro. Pathog."},{"key":"71040_CR42","doi-asserted-by":"publisher","first-page":"RP105195","DOI":"10.7554\/eLife.105195.3","volume":"14","author":"JM Desveaux","year":"2025","unstructured":"Desveaux, J. M. et al. Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of Pseudomonas aeruginosa act through distinct mechanisms. eLife 14, RP105195 (2025).","journal-title":"eLife"},{"key":"71040_CR43","first-page":"3402","volume":"52","author":"T Yokota","year":"1992","unstructured":"Yokota, T., Milenic, D. E., Whitlow, M. & Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52, 3402\u20133408 (1992).","journal-title":"Cancer Res"},{"key":"71040_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1046\/j.1365-2249.2002.01808.x","volume":"128","author":"MA Thiel","year":"2002","unstructured":"Thiel, M. A. et al. Penetration of engineered antibody fragments into the eye. Clin. Exp. Immunol. 128, 67\u201374 (2002).","journal-title":"Clin. Exp. Immunol."},{"key":"71040_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13223-021-00574-x","volume":"17","author":"A Baylet","year":"2021","unstructured":"Baylet, A. et al. Transcutaneous penetration of a single-chain variable fragment (scFv) compared to a full-size antibody: potential tool for atopic dermatitis (AD) treatment. Allergy Asthma Clin. Immunol. 17, 73 (2021).","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"71040_CR46","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1093\/emboj\/cdg290","volume":"22","author":"H Sato","year":"2003","unstructured":"Sato, H. et al. The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU. EMBO J. 22, 2959\u20132969 (2003).","journal-title":"EMBO J."},{"key":"71040_CR47","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1097\/01.CCM.0000145588.79063.07","volume":"32","author":"RR Pankhaniya","year":"2004","unstructured":"Pankhaniya, R. R. et al. Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU. Crit. Care Med. 32, 2293\u20132299 (2004).","journal-title":"Crit. Care Med."},{"key":"71040_CR48","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1086\/379372","volume":"188","author":"GS Schulert","year":"2003","unstructured":"Schulert, G. S. et al. Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J. Infect. Dis. 188, 1695\u20131706 (2003).","journal-title":"J. Infect. Dis."},{"key":"71040_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-014-0668-9","volume":"18","author":"T Sawa","year":"2014","unstructured":"Sawa, T., Shimizu, M., Moriyama, K. & Wiener-Kronish, J. P. Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review. Crit. Care 18, 668 (2014).","journal-title":"Crit. Care"},{"key":"71040_CR50","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/cid\/ciu866","volume":"60","author":"C Pena","year":"2015","unstructured":"Pena, C. et al. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin. Infect. Dis. 60, 539\u2013548 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"71040_CR51","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1016\/j.cell.2023.10.002","volume":"186","author":"A Simonis","year":"2023","unstructured":"Simonis, A. et al. Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa. Cell 186, 5098\u20135113 e5019 (2023).","journal-title":"Cell"},{"key":"71040_CR52","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1128\/IAI.72.8.4741-4750.2004","volume":"72","author":"J Goure","year":"2004","unstructured":"Goure, J. et al. The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB\/PopD translocation pore in host cell membranes. Infect. Immun. 72, 4741\u20134750 (2004).","journal-title":"Infect. Immun."},{"key":"71040_CR53","doi-asserted-by":"publisher","first-page":"e0238122","DOI":"10.1128\/mbio.02381-22","volume":"13","author":"E Kundracik","year":"2022","unstructured":"Kundracik, E., Trichka, J., Diaz Aponte, J., Roistacher, A. & Rietsch, A. PopB-PcrV interactions are essential for pore formation in the Pseudomonas aeruginosa type III secretion system translocon. mBio 13, e0238122 (2022).","journal-title":"mBio"},{"key":"71040_CR54","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2174\/1567205013666161108110031","volume":"14","author":"F Perche","year":"2017","unstructured":"Perche, F. et al. Improved brain expression of anti-amyloid beta scFv by complexation of mRNA including a secretion sequence with PEG-based block catiomer. Curr. Alzheimer Res. 14, 295\u2013302 (2017).","journal-title":"Curr. Alzheimer Res."},{"key":"71040_CR55","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.15252\/emmm.201707678","volume":"9","author":"M Thran","year":"2017","unstructured":"Thran, M. et al. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol. Med. 9, 1434\u20131447 (2017).","journal-title":"EMBO Mol. Med."},{"key":"71040_CR56","doi-asserted-by":"publisher","first-page":"e0161222","DOI":"10.1128\/mbio.01612-22","volume":"13","author":"B Chen","year":"2022","unstructured":"Chen, B. et al. A single dose of anti-HBsAg antibody-encoding mRNA-LNPs suppressed HBsAg expression: a potential cure of chronic Hepatitis B virus infection. mBio 13, e0161222 (2022).","journal-title":"mBio"},{"key":"71040_CR57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12866-023-03080-9","volume":"24","author":"E Basardeh","year":"2024","unstructured":"Basardeh, E. et al. Anti-Acinetobacter baumannii single-chain variable fragments provide therapeutic efficacy in an immunocompromised mouse pneumonia model. BMC Microbiol. 24, 55 (2024).","journal-title":"BMC Microbiol."},{"key":"71040_CR58","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1067\/mai.2001.116576","volume":"108","author":"TK Hart","year":"2001","unstructured":"Hart, T. K. et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J. Allergy Clin. Immunol. 108, 250\u2013257 (2001).","journal-title":"J. Allergy Clin. Immunol."},{"key":"71040_CR59","doi-asserted-by":"publisher","first-page":"23514","DOI":"10.1074\/jbc.M604292200","volume":"281","author":"WF Dall\u2019Acqua","year":"2006","unstructured":"Dall\u2019Acqua, W. F., Kiener, P. A. & Wu, H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281, 23514\u201323524 (2006).","journal-title":"J. Biol. Chem."},{"key":"71040_CR60","doi-asserted-by":"publisher","first-page":"e97844","DOI":"10.1172\/jci.insight.97844","volume":"3","author":"MJ Borrok","year":"2018","unstructured":"Borrok, M. J. et al. Enhancing IgG distribution to lung mucosal tissue improves protective effect of anti-Pseudomonas aeruginosa antibodies. JCI Insight 3, e97844 (2018).","journal-title":"JCI Insight"},{"key":"71040_CR61","doi-asserted-by":"publisher","first-page":"e56220","DOI":"10.1371\/journal.pone.0056220","volume":"8","author":"S Uchida","year":"2013","unstructured":"Uchida, S. et al. In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle. PLoS One 8, e56220 (2013).","journal-title":"PLoS One"},{"key":"71040_CR62","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"217","author":"N Pardi","year":"2015","unstructured":"Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control Release 217, 345\u2013351 (2015).","journal-title":"J. Control Release"},{"key":"71040_CR63","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","volume":"21","author":"D An","year":"2017","unstructured":"An, D. et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 21, 3548\u20133558 (2017).","journal-title":"Cell Rep."},{"key":"71040_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38244-8","volume":"14","author":"M Inagaki","year":"2023","unstructured":"Inagaki, M. et al. Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures. Nat. Commun. 14, 2657 (2023).","journal-title":"Nat. Commun."},{"key":"71040_CR65","doi-asserted-by":"publisher","first-page":"e2413016","DOI":"10.1002\/advs.202413016","volume":"12","author":"K Iwakawa","year":"2025","unstructured":"Iwakawa, K. et al. Cubic phase-inducible zwitterionic phospholipids improve the functional delivery of mRNA. Adv. Sci. 12, e2413016 (2025).","journal-title":"Adv. Sci."},{"key":"71040_CR66","first-page":"100972","volume":"43","author":"C Zhang","year":"2024","unstructured":"Zhang, C., Fu, X., Liu, Y., Zhao, H. & Wang, G. Burden of infectious diseases and bacterial antimicrobial resistance in China: a systematic analysis for the global burden of disease study 2019. Lancet Reg. Health West Pac. 43, 100972 (2024).","journal-title":"Lancet Reg. Health West Pac."},{"key":"71040_CR67","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/s41565-024-01765-4","volume":"19","author":"S Zhao","year":"2024","unstructured":"Zhao, S. et al. Acid-degradable lipid nanoparticles enhance the delivery of mRNA. Nat. Nanotechnol. 19, 1702\u20131711 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"71040_CR68","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1086\/341069","volume":"186","author":"DW Frank","year":"2002","unstructured":"Frank, D. W. et al. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J. Infect. Dis. 186, 64\u201373 (2002).","journal-title":"J. Infect. Dis."},{"key":"71040_CR69","doi-asserted-by":"publisher","first-page":"e2214320120","DOI":"10.1073\/pnas.2214320120","volume":"120","author":"TA Tockary","year":"2023","unstructured":"Tockary, T. A. et al. Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment. Proc. Natl. Acad. Sci. USA 120, e2214320120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71040_CR70","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.ymthe.2024.03.022","volume":"32","author":"S Abbasi","year":"2024","unstructured":"Abbasi, S. et al. Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity. Mol. Ther. 32, 1266\u20131283 (2024).","journal-title":"Mol. Ther."},{"key":"71040_CR71","first-page":"572","volume":"13","author":"BW Holloway","year":"1955","unstructured":"Holloway, B. W. Genetic recombination in Pseudomonas aeruginosa. J. Gen. Microbiol. 13, 572\u2013581 (1955).","journal-title":"J. Gen. Microbiol."},{"key":"71040_CR72","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/35023079","volume":"406","author":"CK Stover","year":"2000","unstructured":"Stover, C. K. et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406, 959\u2013964 (2000).","journal-title":"Nature"},{"key":"71040_CR73","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/infdis\/116.4.481","volume":"116","author":"PV Liu","year":"1966","unstructured":"Liu, P. V. The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. 3. Identity of the lethal toxins produced in vitro and in vivo. J. Infect. Dis. 116, 481\u2013489 (1966).","journal-title":"J. Infect. Dis."},{"key":"71040_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-595","volume":"11","author":"KA Jolley","year":"2010","unstructured":"Jolley, K. A. & Maiden, M. C. BIGSdb: Scalable analysis of bacterial genome variation at the population level. BMC Bioinforma. 11, 595 (2010).","journal-title":"BMC Bioinforma."},{"key":"71040_CR75","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"71040_CR76","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1128\/AAC.37.2.164","volume":"37","author":"K Oishi","year":"1993","unstructured":"Oishi, K. et al. Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia. Antimicrob. Agents Chemother. 37, 164\u2013170 (1993).","journal-title":"Antimicrob. Agents Chemother."},{"key":"71040_CR77","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1097\/CCM.0000000000001271","volume":"44","author":"H Katoh","year":"2016","unstructured":"Katoh, H. et al. IV immunoglobulin for acute lung injury and bacteremia in Pseudomonas aeruginosa pneumonia. Crit. Care Med. 44, e12\u2013e24 (2016).","journal-title":"Crit. Care Med."},{"key":"71040_CR78","unstructured":"theLabRats. Protocol for assay of myeloperoxidase in frozen Lung tissue in the LabRat.com., http:\/\/www.thelabrat.com\/protocols\/myeloperoxidaseassay.shtml (2005)."},{"key":"71040_CR79","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"71040_CR80","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1016\/j.biomaterials.2013.12.012","volume":"35","author":"S Uchida","year":"2014","unstructured":"Uchida, S. et al. An injectable spheroid system with genetic modification for cell transplantation therapy. Biomaterials 35, 2499\u20132506 (2014).","journal-title":"Biomaterials"},{"key":"71040_CR81","doi-asserted-by":"publisher","first-page":"23940","DOI":"10.1074\/jbc.M803146200","volume":"283","author":"C Gebus","year":"2008","unstructured":"Gebus, C., Faudry, E., Bohn, Y. S., Elsen, S. & Attree, I. Oligomerization of PcrV and LcrV, protective antigens of Pseudomonas aeruginosa and Yersinia pestis. J. Biol. Chem. 283, 23940\u201323949 (2008).","journal-title":"J. Biol. Chem."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71040-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71040-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71040-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:03:42Z","timestamp":1775725422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71040-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71040"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71040-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.K., S.U., and T.S. filed a patent on passive immunotherapy with anti-\n                      Pseudomonas\n                      single-chain antibody mRNA in Japan (application number: 2024-187725). S.U. is a founder of Crafton Biotechnology. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2960"}}